Clinical Trials in ALS: An Overview

Martin R. Turner; Matthew J. Parton; P. Nigel Leigh

doi:10.1055/s-2001-15262

Seminars in Neurology, Table of Contents

Semin Neurol 2001; 21(2): 167-176
DOI: 10.1055/s-2001-15262

Clinical Trials in ALS: An Overview

Martin R. Turner, Matthew J. Parton, P. Nigel Leigh

MND Care and Research Centre, Department of Neurology, Guy's, King's and St Thomas' School of Medicine and the Institute of Psychiatry, London, United Kingdom

Abstract

ABSTRACT

Clinical trials in amyotrophic lateral sclerosis (ALS) have been conducted for over half a century now and have incorporated a wide variety of drugs. Most of these trials have had negative results and a cure remains elusive. The explosion in our understanding of molecular biology and parallel developments in clinical epidemiology have opened up a vast number of novel therapeutic strategies. However, advances in statistical analysis, computing, and global communications have also put greater pressure on scientific investigators to improve the design and implementation of clinical trials so that they permit rigorous testing of hypotheses within a solid ethical framework. This article documents the first published trial for all drugs tried clinically in the treatment of ALS, focusing in more detail on the large, multicenter trials of recent years, namely those involving riluzole, ciliary neurotrophic factor, insulin-like growth factor-I, brain-derived neurotrophic factor, and SR57746A. The problems in the design of trials in ALS are discussed, including the selection of end points and surrogate markers of disease progression, and the major parameters in ALS assessment are reviewed.

KEYWORD

Amyotrophic lateral sclerosis - motor neuron disease - clinical trial - end point - surrogate marker - riluzole - ciliary neurotrophic factor - insulin-like growth factor-I - brain-derived neurotrophic factor - SR57746A

Full Text

References

REFERENCES

1 Liversedge L A. Glycocyamine and betaine in motor-neurone disease. Lancet . 1956; 2 1136-1138
2 Charcot J M. De la sclérose latérale amyotrophique. Prog Med . 1874; 2 325, 341-453
3 Denker P G, Scheinman L. Treatment of amyotrophic lateral sclerosis with vitamin E (alpha-tocopherol). JAMA . 1941; 116 1893-1895
4 Fareed G C, Tyler H R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology . 1971; 21 937-940
5 Norris Jr H F, Calanchini P R, Fallat R J, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology . 1974; 24 721-728
6 Bunina T L, Khondkarian O A, Korshunova T S, Larskii E G, Fuks B B. Treatment of amyotrophic lateral sclerosis with ribonucleotides. Zh Nevropatol Psikhiatr Im S S Korsakova . 1976; 76 166-174
7 Olson W H, Simons J A, Halaas G W. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. Neurology . 1978; 28 1293-1295
8 Norris Jr H F, KS U, Sachais B, Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol . 1979; 36 715-716
9 Munsat T L, Easterday C S, Levy S, Wolff S M, Hiatt R. Amantadine and guanidine are ineffective in ALS. Neurology . 1981; 31 1054-1055
10 Engel W K, Siddique T, Nicoloff J T. Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet . 1983; 2 73-75
11 Kelemen J, Hedlund W, Orlin J B, Berkman E M, Munsat T L. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol . 1983; 40 752-753
12 Bradley W G, Hedlund W, Cooper C. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology . 1984; 34 1079-1082
13 Olarte M R, Shafer S Q. Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology . 1985; 35 1063-1066
14 Norris F H, Denys E H, Fallat R J. Trial of octacosanol in amyotrophic lateral sclerosis. Neurology . 1986; 36 1263-1264
15 Mora J S, Munsat T L, Kao K P. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology . 1986; 36 1137-1140
16 Brown Jr H R, Hauser S L, Harrington H, Weiner H L. Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol . 1986; 43 383-384
17 Aquilonius S M, Askmark H, Eckernas S A. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis: a controlled study of physostigmine versus neostigmine. Acta Neurol Scand . 1986; 73 628-632
18 Provinciali L, Giovagnoli A R, Di Bella P, Baroni M, Dellantonio R. A therapeutic trial of thymic factor in amyotrophic lateral sclerosis (ALS). Adv Exp Med Biol . 1987; 209 293-296
19 Plaitakis A, Smith J, Mandeli J, Yahr M D. Pilot trial of branched-chain amino-acids in amyotrophic lateral sclerosis. Lancet . 1988; 1 1015-1018
20 Appel S H, Stewart S S, Appel V. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol . 1988; 45 381-386
21 Werdelin L, Boysen G, Jensen T S, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand . 1990; 82 132-134
22 Szulc-Kuberska J, Klimek A, Stepien H, Woszczak M. Clinical trial of the treatment of amyotrophic lateral sclerosis with bromocriptine. Neurol Neurochir Pol . 1990; 24 37-41
23 Askmark H, Aquilonius S M, Gillberg P G. Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand . 1990; 82 253-258
24 Nevsimal O, Pekarek J, Koubek K, Cech K, Sonkova Z. Low-molecular transfer factor and its use in the treatment of amyotrophic lateral sclerosis. Cesk Neurol Neurochir . 1991; 54 220-222
25 Testa D, Caraceni T, Fetoni V, Girotti F. Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. Clin Neurol Neurosurg . 1992; 94 7-9
26 Majkowski J. Long-term treatment of amyotrophic lateral sclerosis with phthalazinol. Adv Second Messenger Phosphoprotein Res . 1992; 25 409-416
27 Westarp M E, Westphal K P, Kolde G. Dermal, serological and CSF changes in amyotrophic lateral sclerosis with and without intrathecal interferon beta treatment. Int J Clin Pharmacol Ther Toxicol . 1992; 30 81-93
28 Smith R A, Melmed S, Sherman B. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve . 1993; 16 624-633
29 Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci . 1993; 20 297-301
30 Drachman D B, Chaudhry V, Cornblath D. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol . 1994; 35 142-150
31 Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol . 1994; 241 223-227
32 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med . 1994; 330 585-591
33 Louwerse E S, Weverling G J, Bossuyt P M, Meyjes F E, de Jong M J. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol . 1995; 52 559-564
34 Handa I, Matsushita N, Ihashi K. A clinical trial of therapeutic electrical stimulation for amyotrophic lateral sclerosis. Tohoku J Exp Med . 1995; 175 123-134
35 Vyth A, Timmer J G, Bossuyt P M, Louwerse E S, de Jong M J. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci (suppl). 1996; 139 (99-103)
36 Miller R G, Smith S A, Murphy J R. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve . 1996; 19 511-515
37 Miller R G, Shepherd R, Dao H. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord . 1996; 6 101-104
38 Aisen M L, Sevilla D, Edelstein L, Blass J. A double-blind placebo-controlled study of 3,4-diaminopyridine in amyotrophic lateral sclerosis patients on a rehabilitation unit. J Neurol Sci . 1996; 138 93-96
39 Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol . 1996; 243 117-120
40 The ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology . 1996; 46 1244-1249
41 Lange D J, Felice K J, Festoff B W. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology (suppl 2). 1996; 47 (S93-S94)
42 Miller R G, Moore D, Young L A. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology . 1996; 47 1383-1388
43 Cudkowicz M E, Warren L, Francis J W. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology . 1997; 49 213-222
44 Szczudlik A, Tomik B, Slowik A, Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis: introductory notes. Neurol Neurochir Pol . 1998; 32 821-829
45 Kaji R, Kodama M, Imamura A. Effect of ultrahigh-dose methylcoba lamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve . 1998; 21 1775-1778
46 Cudkowicz M E, Sexton P M, Ellis T. The pharmacokinetics and pharmacodynamics of Procysteine in amyotrophic lateral sclerosis. Neurology . 1999; 52 1492-1494
47 The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology . 1999; 52 1427-1433
48 Miller R G, Munsat T L, Swash M, Brooks B R. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci . 1999; 169 2-12
49 Haverkamp L J, Appel V, Appel S H. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain . 1995; 118 707-719
50 Munsat T L. Issues in amyotrophic lateral sclerosis clinical trial design. Adv Neurol . 1995; 68 209-218
51 Brooks B R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ``Clinical limits of amyotrophic lateral sclerosis'' workshop contributors. J Neurol Sci (suppl). 1994; 124 (96-107)
52 Munsat T L. Issues in clinical trial design I: use of natural history controls: a protagonist view. Neurology . 1996; 47(4 suppl 2) S96-S97
53 Miller R G, Mitchell J D, Moore D H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev . 2000; 2 CD001447
54 Armon C. How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?. ALS Other Motor Neuron Disord . 1999; 1 3-14
55 Mills K R. Motor neuron disease: studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation. Brain . 1995; 118 971-982
56 Pioro E P. Proton magnetic resonance spectroscopy (¹H-MRS) in ALS. ALS Other Motor Neuron Disord (suppl 2). 2000; 1 (S7-S16)
57 Turner M R, Leigh P N. Positron emission tomography (PET): its potential to provide surrogate markers in ALS. ALS Other Motor Neuron Disord (suppl 2). 2000; 1 (S17-S22)
58 Eisen A, Krieger C. ALS therapy, therapeutic trials, and neuroprotection. In: Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice Cambridge: Cambridge University Press 1998: 209-237
59 Fitting J W, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol . 1999; 46 887-893
60 Andres P L, Hedlund W, Finison L. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology . 1986; 36 937-941
61 Appel V, Stewart S S, Smith G, Appel S H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol . 1987; 22 328-333
62 The ALS CNTF treatment study (ACTS) phase I-II Study Group. The amyo- trophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol . 1996; 53 141-147
63 Bergner M, Bobbitt R A, Carter W B, Gilson B S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care . 1981; 19 787-805
64 McGuire D, Garrison L, Armon C. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. Neurology . 1996; 46 1442-1444
65 McGuire D, Garrison L, Armon C. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. J Neurol Sci (suppl 1) . 1997; 152 (S18-S22)
66 Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol (suppl 3). 1999; 246 (III16-III21)
67 Plaitakis A, Caroscio J T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol . 1987; 22 575-579
68 Ince P, Eggett C J, Shaw P J. The role of excitotoxicity in neurological disease. Rev Contemp Pharmacother . 1997; 8 195-212
69 Lacomblez L, Bensimon G, Leigh P N, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet . 1996; 347 1425-1431
70 Martinou J C, Martinou I, Kato A C. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro. Neuron . 1992; 8 737-744
71 Mitsumoto H, Ikeda K, Klinkosz B. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science . 1994; 265 1107-1110
72 Miller R G, Bryan W W, Dietz M A. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology . 1996; 47 1329-1331
73 Stambler N, Charatan M, Cedarbaum J M. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology . 1998; 50 66-72
74 Lewis M E, Neff N T, Contreras P C. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol . 1993; 124 73-88
75 Neff N T, Prevette D, Houenou L J. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol . 1993; 24 1578-1588
76 Lai E C, Felice K J, Festoff B W. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology . 1997; 49 1621-1630
77 Borasio G D, Robberecht W, Leigh P N. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology . 1998; 51 583-586
78 Ackerman S J, Sullivan E M, Beusterien K M. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics . 1999; 15 179-195
79 Henderson C E, Bloch-Gallego E, Camu W. Motoneuron survival factors: biological roles and therapeutic potential. Neuromuscul Disord . 1993; 3 455-458
80 Ikeda K, Klinkosz B, Greene T. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol . 1995; 37 505-511
81 Fournier J, Steinberg R, Gauthier T. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience . 1993; 55 629-641